DNMT1 and cancer: The serious side effects of different DNMT and HDAC inhibitors (decitabine, Trichostatin, etc.), which are currently under use for the treatment of cancer patients, as well as the unsafe cytotoxic profile and non-specificity of the drugs warrants a quest for safer drug candidates [12].